NZ617520A - Drug selection for breast cancer therapy using antibody-based arrays - Google Patents

Drug selection for breast cancer therapy using antibody-based arrays

Info

Publication number
NZ617520A
NZ617520A NZ617520A NZ61752009A NZ617520A NZ 617520 A NZ617520 A NZ 617520A NZ 617520 A NZ617520 A NZ 617520A NZ 61752009 A NZ61752009 A NZ 61752009A NZ 617520 A NZ617520 A NZ 617520A
Authority
NZ
New Zealand
Prior art keywords
antibody
breast cancer
cancer therapy
drug selection
based arrays
Prior art date
Application number
NZ617520A
Other languages
English (en)
Inventor
Sharat Singh
Jeanne Harvey
Phillip Kim
Xinjun Liu
Limin Liu
Robert Barham
Bruce Neri
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of NZ617520A publication Critical patent/NZ617520A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ617520A 2008-02-25 2009-02-24 Drug selection for breast cancer therapy using antibody-based arrays NZ617520A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US3131908P 2008-02-25 2008-02-25
US10640408P 2008-10-17 2008-10-17
US10838408P 2008-10-24 2008-10-24
US11790808P 2008-11-25 2008-11-25
US14055808P 2008-12-23 2008-12-23
NZ600339A NZ600339A (en) 2008-02-25 2009-02-24 Drug selection for breast cancer therapy using antibody-based arrays

Publications (1)

Publication Number Publication Date
NZ617520A true NZ617520A (en) 2015-05-29

Family

ID=40599946

Family Applications (3)

Application Number Title Priority Date Filing Date
NZ587420A NZ587420A (en) 2008-02-25 2009-02-24 Drug selection for breast cancer therapy using antibody-based arrays
NZ600339A NZ600339A (en) 2008-02-25 2009-02-24 Drug selection for breast cancer therapy using antibody-based arrays
NZ617520A NZ617520A (en) 2008-02-25 2009-02-24 Drug selection for breast cancer therapy using antibody-based arrays

Family Applications Before (2)

Application Number Title Priority Date Filing Date
NZ587420A NZ587420A (en) 2008-02-25 2009-02-24 Drug selection for breast cancer therapy using antibody-based arrays
NZ600339A NZ600339A (en) 2008-02-25 2009-02-24 Drug selection for breast cancer therapy using antibody-based arrays

Country Status (13)

Country Link
US (4) US8163499B2 (es)
EP (3) EP2250498B1 (es)
JP (2) JP5414701B2 (es)
CN (2) CN102016581B (es)
AU (1) AU2009219437B2 (es)
CA (2) CA2923248A1 (es)
DK (2) DK2250498T3 (es)
ES (3) ES2398618T3 (es)
HK (2) HK1182441A1 (es)
IL (3) IL207637A (es)
MX (1) MX2010009140A (es)
NZ (3) NZ587420A (es)
WO (1) WO2009108637A1 (es)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2949658T3 (en) * 2003-03-03 2018-10-01 Dyax Corp Peptides that specifically bind HGF receptor (cMet) and uses thereof
NZ556673A (en) 2005-02-03 2010-03-26 Gen Hospital Corp Method for treating gefitinib and/or erlotinib resistant cancer with an EGFR inhibitor
KR101354828B1 (ko) 2005-11-04 2014-02-18 와이어쓰 엘엘씨 ｍＴＯＲ 저해자, 헤르셉틴, 및/또는 ＨＫＩ-272의항신생물성 조합
BRPI0717416A2 (pt) 2006-09-21 2013-11-12 Prometheus Lab Inc Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo
RU2519647C2 (ru) 2007-07-13 2014-06-20 Нестек С.А. Выбор лекарственных средств для терапии рака легких с помощью матриц на основе антител
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
NZ587420A (en) 2008-02-25 2012-07-27 Prometheus Lab Inc Drug selection for breast cancer therapy using antibody-based arrays
EP3730139B1 (en) 2008-06-17 2023-08-16 Wyeth LLC Antineoplastic combinations containing hki-272 and vinorelbine
KR101434009B1 (ko) 2008-08-04 2014-08-25 와이어쓰 엘엘씨 4-아닐리노-3-사이아노퀴놀린과 카페시타빈의 항신생물성 조합물
US8583380B2 (en) 2008-09-05 2013-11-12 Aueon, Inc. Methods for stratifying and annotating cancer drug treatment options
WO2010085845A1 (en) * 2009-01-28 2010-08-05 The University Of Queensland Cancer therapy and/or diagnosis
JP5992325B2 (ja) 2009-04-06 2016-09-14 ワイス・エルエルシー 乳癌のための、ネラチニブを活用する治療計画
WO2010132723A1 (en) * 2009-05-14 2010-11-18 Prometheus Laboratories Inc. Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy
PT2473854T (pt) * 2009-06-23 2017-10-17 Fundação D Anna De Sommer Champalimaud E Dr Carlos Montez Champalimaud Sistemas e métodos para tratar, diagnosticar e prever a resposta à terapia do cancro de mama
EP2454598B1 (en) * 2009-07-15 2017-03-22 DiaTech Holdings, Inc. Drug selection for gastric cancer therapy using antibody-based arrays
WO2011015920A2 (en) * 2009-08-03 2011-02-10 Avesthagen Limited A highly efficient process of purification and production of recombinant trastuzumab
WO2011015921A1 (en) * 2009-08-03 2011-02-10 Avesthagen Limited A highly efficient process of purification and production of recombinant cetuximab
WO2011034919A2 (en) * 2009-09-15 2011-03-24 H. Lee Moffitt Cancer Center And Research Institute, Inc. Sh2 domain profiling to characterize tyrosine phosphorylation signaling in cancer
BR112012009296A2 (pt) * 2009-10-20 2021-02-02 Prometheus Laboratories Inc. métodos para determinar o nível ou estado de ativação de uma proteína de fusão oncogênica, para otimizar terapia e/ou reduzir a toxicidade em um sujeito tendo câncer, para selecionar um medicamento anti-câncer adequado para o tratamento de um câncer, para identificar a resposta de um câncer ao tratamento com um medicamento câncer, pra identificar a resposta de um câncer ao tratamento com um medicamento anti-câncer, para predizer a resposta de um sujeito tendo câncer ao tratamento com um medicamento anti-câncer, e, para determinar se um sujeito tendo câncer é resistente ao tratamento com um medicamento anti-câncer.
WO2011088149A2 (en) * 2010-01-12 2011-07-21 Prometheus Laboratories Inc. Methods for predicting response of triple-negative breast cancer to therapy
WO2011087926A1 (en) * 2010-01-13 2011-07-21 Wyeth Llc A CUT-POINT IN PTEN PROTEIN EXPRESSION THAT ACCURATELY IDENTIFIES TUMORS AND IS PREDICTIVE OF DRUG RESPONSE TO A PAN-ErbB INHIBITOR
ES2652600T3 (es) 2010-07-07 2018-02-05 The Regents Of The University Of Michigan Diagnóstico y tratamiento de cáncer de mama
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
IN2013MN00522A (es) 2010-09-24 2015-05-29 Univ Leland Stanford Junior
SG191230A1 (en) 2010-12-23 2013-07-31 Nestec Sa Drug selection for malignant cancer therapy using antibody-based arrays
US9962361B2 (en) 2011-01-03 2018-05-08 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
WO2012106559A1 (en) * 2011-02-02 2012-08-09 Translational Genomics Research Institute Biomarkers and methods of use thereof
US9719995B2 (en) 2011-02-03 2017-08-01 Pierian Holdings, Inc. Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling
US9532969B2 (en) 2011-02-08 2017-01-03 The William M. Yarbrough Foundation Method for treating psoriasis
CN103502815B (zh) 2011-02-17 2015-09-23 雀巢产品技术援助有限公司 检测针对抗-TNFα药物的自身抗体的测定法
CA2826643C (en) 2011-02-17 2016-04-12 Nestec S.A. Apparatus and method for isolating leukocytes and tumor cells by filtration
ES2734673T3 (es) 2011-03-02 2019-12-11 Nestle Sa Predicción de la sensibilidad farmacológica de tumores de pulmón basándose en identificaciones moleculares y genéticas
CN103597354B (zh) * 2011-04-04 2016-04-20 雀巢产品技术援助有限公司 用于预测和改善胃癌患者存活的方法
CA2839792A1 (en) 2011-05-10 2012-11-15 Nestec S.A. Methods of disease activity profiling for personalized therapy management
AU2012296385A1 (en) 2011-08-18 2014-02-20 Nestec S.A. Compositions and methods for detecting allelic variants
WO2013033623A1 (en) 2011-09-02 2013-03-07 Nestec S.A. Profiling of signal pathway proteins to determine therapeutic efficacy
US20140296198A1 (en) * 2011-11-04 2014-10-02 Invivis SAS a corporation Assay For Predictive Biomarkers Of Anti-Estrogen Efficacy
WO2013086031A1 (en) * 2011-12-05 2013-06-13 Nestec S.A. Method of therapy selection for patients with cancer
CN107929732A (zh) * 2011-12-12 2018-04-20 中国科学院生物物理研究所 Cd146及其抗体诊断和治疗三阴性乳腺癌的应用
MX355567B (es) * 2011-12-30 2018-04-23 Quest Diagnostics Invest Inc Aptameros y metodos de diagnostico para detectar el receptor de egf.
US20130330761A1 (en) 2012-06-12 2013-12-12 Celcuity, LLC Whole cell assays and methods
US10434082B2 (en) 2012-07-26 2019-10-08 The William M. Yarbrough Foundation Isothiocyanate functional compounds augmented with secondary antineoplastic medicaments and associated methods for treating neoplasms
US10441561B2 (en) 2012-07-26 2019-10-15 The William M. Yanbrough Foundation Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer
US10335387B2 (en) 2012-07-26 2019-07-02 The William M. Yarbrough Foundation Method for treating infectious diseases with isothiocyanate functional compounds
US10434081B2 (en) 2012-07-26 2019-10-08 The William M. Yarbrough Foundation Inhibitors of macrophage migration inhibitory factor
CN104823053A (zh) * 2012-07-27 2015-08-05 利昂贝拉尔中心 ERα/Src/PI3K复合物的检测作为乳腺癌的预测标志
WO2014054013A1 (en) 2012-10-05 2014-04-10 Nestec S.A. Methods for predicting and monitoring mucosal healing
CA3215087A1 (en) * 2013-01-03 2014-07-10 Meso Scale Technologies, Llc Assay panels
EP2954328A1 (en) 2013-02-05 2015-12-16 Nestec S.A. Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling
WO2014122600A1 (en) 2013-02-05 2014-08-14 Nestec S.A. Methods of selecting combination therapy for colorectal cancer patients
EP2954068B8 (en) 2013-02-05 2018-10-31 Pierian Holdings, Inc. Drug selection for non-small cell lung cancer therapy
AU2014248759B2 (en) 2013-03-13 2020-02-27 Meso Scale Technologies, Llc. Improved assay methods
US10114015B2 (en) 2013-03-13 2018-10-30 Meso Scale Technologies, Llc. Assay methods
CN114592060A (zh) * 2013-03-15 2022-06-07 詹森药业有限公司 预测性生物标记的测定法
CA2909310A1 (en) * 2013-04-12 2014-10-16 Asana Biosciences, Llc Quinazolines and azaquinazolines as dual inhibitors of ras/raf/mek/erk and pi3k/akt/pten/mtor pathways
AU2014269946A1 (en) 2013-05-21 2015-12-03 Nestec S.A. Methods for predicting and improving the survival of colorectal cancer patients
AU2014289499A1 (en) 2013-07-09 2015-11-19 Nestec S.A. Microfluidic collaborative enzyme enhanced reactive CEER immunoassay
WO2015028974A2 (en) 2013-08-30 2015-03-05 Nestec S.A. Polyp recurrence
CA2942081C (en) * 2013-10-11 2021-09-07 Ventana Medical Systems, Inc. Multiplex her2 and estrogen receptor co-staining assays for detecting tumor heterogeneity
US20160273045A1 (en) * 2013-10-23 2016-09-22 Oregon Health & Science University Methods of determining breast cancer prognosis
EP3077538A1 (en) 2013-12-03 2016-10-12 Nestec S.A. Signaling pathways in tissues from inflammatory bowel disease patients
WO2015089380A2 (en) 2013-12-12 2015-06-18 Celcuity Llc Assays and methods for determining the responsiveness of an individual subject to a therapeutic agent
US9730935B2 (en) * 2013-12-13 2017-08-15 The Board Of Trustees Of The Leland Stanford Junior University Targeting a non-canonical notch signaling pathway for cancer treatment
WO2015108342A1 (ko) * 2014-01-14 2015-07-23 최원철 루테리알의 형태특성을 이용한 암 예방제 또는 항암제의 스크리닝 방법
WO2015110989A1 (en) 2014-01-23 2015-07-30 Nestec S.A. Biomarker panel for assessment of mucosal healing
WO2015166461A1 (en) 2014-05-01 2015-11-05 Nestec S.A. Methods of selecting treatment regimen using tnf alpha and anti-tnf alpha drug levels
JP6695280B2 (ja) 2014-05-15 2020-05-20 メソ スケール テクノロジーズ エルエルシー 改善されたアッセイ方法
CN106913870A (zh) * 2014-06-27 2017-07-04 中国科学院生物物理研究所 用于阻断Netrin‑1与CD146之间的相互作用的试剂及其肿瘤治疗用途
CA2964857A1 (en) 2014-10-20 2016-04-28 Nestec S.A. Methods for prediction of anti-tnf alpha drug levels and autoantibody formation
EP3227685A1 (en) 2014-12-02 2017-10-11 Nestec S.A. Methods for establishing a vedolizumab dosing regimen to treat patients with irritable bowel disease
DK3230736T3 (da) * 2014-12-12 2020-06-08 Celcuity Inc Fremgangsmåder til måling af ErbB-signaleringsvejsaktivitet til at diagnosticere og behandle cancerpatienter
EP3270160B1 (en) 2015-03-13 2020-03-18 Sysmex Corporation Method for detecting test substance and reagent kit used in said method
EP3363911B1 (en) * 2015-10-14 2024-09-25 Nitto Boseki Co., Ltd. Method for determining drug-sensitive human breast cancer cells by analysis method in which measurement of activity of two types of protein kinase is used
KR20190015360A (ko) * 2016-05-31 2019-02-13 네스텍 소시에테아노님 Ｈｅｒ2 및 ｈｅｒ3 경로 아형 분류를 기반으로 한, 유방암 환자에 대한 약물 치료법의 선택 방법
CN107727752B (zh) * 2016-08-12 2019-11-08 北大方正集团有限公司 免疫抑制剂依维莫司的分析方法
JP6518985B2 (ja) * 2016-09-29 2019-05-29 住友ゴム工業株式会社 がん細胞捕捉方法
JP6779483B2 (ja) 2016-09-29 2020-11-04 住友ゴム工業株式会社 医療用検査装置及び細胞検査方法
CN106645728A (zh) * 2016-11-09 2017-05-10 百奥森（江苏）食品安全科技有限公司 一种食品中氟喹诺酮类药物的检测试剂盒
EP3551761B1 (en) * 2016-12-07 2022-03-16 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Her2 as a predictor of response to dual her2 blockade in the absence of cytotoxic therapy
KR20220165826A (ko) 2017-03-20 2022-12-15 셀퀴티 인크. 치료제의 선택을 위한 신호전달 경로 활성을 측정하는 방법
KR102575246B1 (ko) 2017-04-18 2023-09-06 일라이 릴리 앤드 캄파니 페닐-2-히드록시-아세틸아미노-2-메틸-페닐 화합물
CA3064529C (en) 2017-05-31 2021-12-14 Prometheus Biosciences, Inc. Methods for assessing mucosal healing in crohn's disease patients
WO2019073391A1 (en) 2017-10-10 2019-04-18 Nestec S.A. METHODS OF MONITORING VEDOLIZUMAB TREATMENT
JP7109719B2 (ja) 2018-02-14 2022-08-01 住友ゴム工業株式会社 特定細胞捕捉方法
JP7158671B2 (ja) 2018-02-14 2022-10-24 住友ゴム工業株式会社 特定細胞捕捉方法
EA202092282A1 (ru) 2018-03-26 2021-01-14 Икан Скул Оф Медсин Эт Маунт Синай Способы лечения минимального остаточного рака
US10871485B2 (en) 2018-04-13 2020-12-22 Rarecyte, Inc. Kits for labeling of biomarkers and methods of using the same
US11614440B2 (en) 2019-01-24 2023-03-28 Sumitomo Rubber Industries, Ltd. Specific cell fractionating and capturing methods
JP6886667B2 (ja) * 2019-03-27 2021-06-16 住友ゴム工業株式会社 がん細胞捕捉方法
MX2023002106A (es) 2020-08-21 2023-03-15 Genzyme Corp Anticuerpos fgfr3 y metodos de uso.
CN113929764B (zh) * 2021-10-15 2023-12-29 中山大学孙逸仙纪念医院 一种乳腺叶状肿瘤分子标志物cd146及其应用

Family Cites Families (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
US5516931A (en) * 1982-02-01 1996-05-14 Northeastern University Release tag compounds producing ketone signal groups
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4690890A (en) 1984-04-04 1987-09-01 Cetus Corporation Process for simultaneously detecting multiple antigens using dual sandwich immunometric assay
SE8500817D0 (sv) 1985-02-20 1985-02-20 Lars Jonsson Halvoppet anestesisystem
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US4975532A (en) 1986-11-28 1990-12-04 Sclavo, Inc. Method to derivatize dextran
US4959306A (en) * 1986-11-28 1990-09-25 Sclavo, Inc. Labeling design for a binding assay reagent
NO884368L (no) 1987-10-02 1989-04-03 Du Pont Immunanalyse ved anvendelse av igg-innfangelsesantistoff og multippel, monoklonalt antistoffpaavisningssystem.
US4855241A (en) * 1988-05-26 1989-08-08 Washington University Tumor diagnostic method
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5192660A (en) 1989-04-24 1993-03-09 The United States Of America As Represented By The Department Of Health And Human Services ELISA methods for the determination of human platelet derived growth factor (PDGF) dimer forms present in human tissues and fluids
US5089419A (en) 1989-08-07 1992-02-18 International Canine Genetics Detection of pregnancy by identification of the c peptide of relaxin in the urine of animals
US5120660A (en) 1989-12-05 1992-06-09 International Canine Genetics, Inc. Method for canine fertility detection
US5532138A (en) 1990-04-26 1996-07-02 Behringwerke Ag Method and kits for determining peroxidatively active catalysts
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
FR2672128B1 (fr) 1991-01-28 1995-08-18 Cis Bio Int Procede de mesure de la luminescence emise dans un dosage par luminescence.
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US6251581B1 (en) 1991-05-22 2001-06-26 Dade Behring Marburg Gmbh Assay method utilizing induced luminescence
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
ATE244763T1 (de) 1992-02-11 2003-07-15 Cell Genesys Inc Erzielen von homozygotem durch zielgerichtete genetische ereignisse
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5332662A (en) 1992-07-31 1994-07-26 Syntex (U.S.A.) Inc. Methods for determining peroxidatively active substances
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
JPH06109734A (ja) 1992-09-30 1994-04-22 S R L:Kk 抗原の測定方法
US6201109B1 (en) 1993-01-13 2001-03-13 Dade Behring Marburg Gmbh Assay for bone alkaline phosphatase
ATE177842T1 (de) 1993-09-03 1999-04-15 Behringwerke Ag Fluoreszenz-sauerstoffkanalisation-immunteste
JP3825815B2 (ja) 1994-01-31 2006-09-27 信義 清水 上皮細胞増殖因子レセプターに対するモノクローナル抗体の結合体ならびにその複合体およびその細胞への嵌入方法
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
FI98961C (fi) 1994-08-26 1997-09-10 Medix Biochemica Ab Oy Menetelmät ja määritysvälineet parodontaalisairauden aktiivisuuden ja/tai peri-implantiitin ja/tai niiden kohonneen riskin diagnosoimiseksi
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5876944A (en) 1996-06-10 1999-03-02 Bayer Corporation Method for amplification of the response signal in a sandwich immunoassay
US5728541A (en) 1996-07-12 1998-03-17 Precision Therapeutics, Inc. Method for preparing cell cultures from biologial specimens for chemotherapeutic and other assays
US6416967B2 (en) 1996-07-12 2002-07-09 Precision Therapeutics, Inc. Method of using multicellular particulates to analyze malignant or hyperproliferative tissue
US20040023375A1 (en) 2002-07-30 2004-02-05 Precision Therapeutics, Inc. Method for preparing cell cultures from biological specimens for chemotherapeutic and other assays
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
US6897073B2 (en) 1998-07-14 2005-05-24 Zyomyx, Inc. Non-specific binding resistant protein arrays and methods for making the same
US6780582B1 (en) 1998-07-14 2004-08-24 Zyomyx, Inc. Arrays of protein-capture agents and methods of use thereof
US6197599B1 (en) 1998-07-30 2001-03-06 Guorong Chin Method to detect proteins
US6541214B1 (en) 1998-11-13 2003-04-01 Oregon Heath Science University N-terminally truncated HER-2/neu protein as a cancer prognostic indicator
RU2165081C2 (ru) 1999-01-05 2001-04-10 Ставропольский научно-исследовательский противочумный институт Способ индикации микроорганизмов
US6335173B1 (en) 1999-01-12 2002-01-01 Verve, Ltd. C/O James Bell Methods for detecting an analyte of interest using tyramide coating technology
GB9901072D0 (en) 1999-01-19 1999-03-10 Imp Cancer Res Tech Methods for detecting changes to a macromolecular component of a cell
US6972198B2 (en) 1999-02-26 2005-12-06 Cyclacel, Ltd. Methods and compositions using protein binding partners
RU2149404C1 (ru) 1999-03-24 2000-05-20 Московский НИИ глазных болезней им. Гельмгольца Способ прогнозирования клинического течения увеальной меланомы
US6322980B1 (en) 1999-04-30 2001-11-27 Aclara Biosciences, Inc. Single nucleotide detection using degradation of a fluorescent sequence
US6627400B1 (en) 1999-04-30 2003-09-30 Aclara Biosciences, Inc. Multiplexed measurement of membrane protein populations
US6649351B2 (en) 1999-04-30 2003-11-18 Aclara Biosciences, Inc. Methods for detecting a plurality of analytes by mass spectrometry
DE19926010C2 (de) 1999-06-08 2003-01-30 Bundesdruckerei Gmbh Wert- und Sicherheitsdokument mit Sicherheitsmerkmal mit Piezo-Effekt-basierten Eigenschaften und dazugehöriges Nachweisverfahren
US7179638B2 (en) 1999-07-30 2007-02-20 Large Scale Biology Corporation Microarrays and their manufacture by slicing
US7033781B1 (en) * 1999-09-29 2006-04-25 Diversa Corporation Whole cell engineering by mutagenizing a substantial portion of a starting genome, combining mutations, and optionally repeating
CA2383945A1 (en) * 1999-10-08 2001-04-19 Li Shen Compositions and methods for detecting protein modification and enzymatic activity
JP2003511696A (ja) 1999-10-13 2003-03-25 インサイト・ゲノミックス・インコーポレイテッド 多重的サイトカイン分析
US7537938B2 (en) 2000-04-28 2009-05-26 Monogram Biosciences, Inc. Biomarker detection in circulating cells
US6511809B2 (en) 2000-06-13 2003-01-28 E. I. Du Pont De Nemours And Company Method for the detection of an analyte by means of a nucleic acid reporter
EP1307285A2 (en) 2000-08-03 2003-05-07 Massachusetts Institute Of Technology Microarrays of functional biomolecules, and uses therefor
AU2001288437C1 (en) * 2000-09-09 2009-05-21 The Research Foundation Of State University Of New York Method and compositions for isolating metastatic cancer cells, and use in measuring metastatic potential of a cancer thereof
US6797481B1 (en) 2000-10-17 2004-09-28 Dade Behring Marburg Gmbh Simultaneous screening of multiple analytes
US7635571B2 (en) 2000-12-07 2009-12-22 Siemens Healthcare Diagnostics Products Gmbh Amplified signal in binding assays
DE10064827A1 (de) 2000-12-22 2002-06-27 Dade Behring Marburg Gmbh Nachweisverfahren
US20070111944A1 (en) * 2001-02-16 2007-05-17 Scrofani Sergio D B Purification of vascular endothelial growth factor-B
US20020168641A1 (en) 2001-03-09 2002-11-14 Bruce Mortensen Fluorescein-cyanine 5 as a fluorescence resonance energy transfer pair
US20020142361A1 (en) 2001-03-27 2002-10-03 Emmert-Buck Michael R. Biodetection method
AU2002303384A1 (en) 2001-04-17 2002-10-28 William J. Dower Epitope-captured antibody display
WO2002090964A1 (en) 2001-05-03 2002-11-14 Genometrix Genomics, Inc. Method and apparatus to determine the performance of protein arrays
US20030059811A1 (en) 2001-06-14 2003-03-27 Hakim Djaballah Methods of screening for ligands of target molecules
US7381535B2 (en) 2002-07-10 2008-06-03 The Board Of Trustees Of The Leland Stanford Junior Methods and compositions for detecting receptor-ligand interactions in single cells
US7695926B2 (en) 2001-07-10 2010-04-13 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detecting receptor-ligand interactions in single cells
JP2005500045A (ja) 2001-07-12 2005-01-06 ルードビッヒ、インスティテュート、フォー、キャンサー、リサーチ リンパ管内皮細胞材料および方法
JP2003028874A (ja) * 2001-07-12 2003-01-29 Mitsubishi Chemicals Corp ２段階酵素反応を用いた測定対象物質の測定法
US8323903B2 (en) 2001-10-12 2012-12-04 Life Technologies Corporation Antibody complexes and methods for immunolabeling
US20050069962A1 (en) 2001-10-12 2005-03-31 Archer Robert M Antibody complexes and methods for immunolabeling
EP1461617A4 (en) 2001-11-07 2005-09-14 Sensor Technologies Llc METHOD FOR IDENTIFYING ENERGY TRANSFER SENSORS FOR ANALYTES
AU2003222253A1 (en) 2002-03-05 2003-09-22 Monogram Biosciences, Inc. Multiplex analysis using membrane-bound sensitizers
US20030190689A1 (en) * 2002-04-05 2003-10-09 Cell Signaling Technology,Inc. Molecular profiling of disease and therapeutic response using phospho-specific antibodies
WO2003087761A2 (en) * 2002-04-05 2003-10-23 Cell Signaling Technology, Inc. Molecular profiling of disease and therapeutic response using phospho-specific antibodies
US20040229380A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB heterodimers as biomarkers
EP2263691B1 (en) 2002-07-15 2012-08-29 F.Hoffmann-La Roche Ag Treatment of cancer with the recombinant humanized monoclonal anti-erbb2 antibody 2C4 (rhuMAb 2C4)
FR2843126B1 (fr) 2002-08-01 2006-01-27 Cis Bio Int "methode de determination d'une activite enzymatique endoglycosidase"
US20040235002A1 (en) 2002-09-20 2004-11-25 Sangamo Biosciences, Inc. Multiplex screening assays
US20030153013A1 (en) 2002-11-07 2003-08-14 Ruo-Pan Huang Antibody-based protein array system
CA2509543C (en) * 2002-12-11 2017-06-06 Ventana Medical Systems, Inc. Method for predicting the response to her2-directed therapy
CA2515096A1 (en) 2003-02-06 2004-08-26 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
BRPI0408961A (pt) 2003-04-01 2006-10-31 Monogram Biosciences Inc método para determinar uma situação de doença de um paciente, método para selecionar um paciente para tratamento de um cáncer com um ou mais medicamentos de ação dimérica de erbb, e, método para determinar uma situação cancerosa de um paciente
US20040265938A1 (en) 2003-06-25 2004-12-30 Jose Remacle Method for the determination of cell activation
US7279286B2 (en) 2003-09-11 2007-10-09 Sanofi-Aventis Deutschland Gmbh High-throughput-assay with high sensitivity for measuring of the activity of β-adrenergic receptor kinase and for determining the impact of test substances on such activity
FI20031370A0 (fi) 2003-09-23 2003-09-23 Wallac Oy Automaattinen hemoglobiinin määritysmenetelmä vastasyntyneiden seulontaan
US7402399B2 (en) 2003-10-14 2008-07-22 Monogram Biosciences, Inc. Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy
ES2343840T3 (es) 2003-11-04 2010-08-11 Bayer Healthcare Llc Procedimientos inmunohistoquimicos para supervisar los niveles de perk.
EP1694865A4 (en) * 2003-12-12 2007-06-06 Bayer Pharmaceuticals Corp METHOD OF PREDICTING AND PROGNOSING CANCER AND MONITORING ANTICANCER TREATMENT
AU2004318038A1 (en) 2004-03-03 2005-10-13 Zeptosens Ag Analytical platform and method for generating protein expression profiles of cell populations
CA2567293C (en) 2004-05-27 2017-05-16 The Regents Of The University Of Colorado Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients
GT200500155A (es) 2004-06-16 2006-05-15 Terapia del càncer resistente al platino
US20060263837A1 (en) 2004-06-17 2006-11-23 Liu George D Immunoassay system and method for detection of antigens
US20060024722A1 (en) 2004-07-30 2006-02-02 Mark Fischer-Colbrie Samples for detection of oncofetal fibronectin and uses thereof
WO2006031815A2 (en) 2004-09-13 2006-03-23 Monogram Biosciences, Inc. Methods and compositions for proximity assays
US20080254497A1 (en) * 2004-10-15 2008-10-16 Monogram Biosciences, Inc. Response Predictors for Erbb Pathway-Specific Drugs
WO2006045991A1 (en) 2004-10-25 2006-05-04 Astrazeneca Ab Method to predict whether a tumor will react to a chemotherapeutic treatment
CA2587765A1 (en) 2004-11-17 2006-05-26 Immunivest Corporation Magnetic enrichment of circulating cells, fragments and debris for enabling hts proteomics and genomics in disease detection
WO2006055739A2 (en) 2004-11-17 2006-05-26 Robert Sack Stationary phase antibody arrays for trace protein analysis
DE102004056794B4 (de) 2004-11-24 2010-08-26 Protagen Ag Verwendung einer Anordnung und Verfahren zur Validierung von Bindern
WO2006105642A1 (en) 2005-04-05 2006-10-12 British Columbia Cancer Agency Biomarkers for the detection of lung cancer and uses thereof
JP4851730B2 (ja) * 2005-05-09 2012-01-11 小澤 滿 除塵加湿装置
AR053272A1 (es) 2005-05-11 2007-04-25 Hoffmann La Roche Determinacion de responsivos a la quimioterapia
US7771955B2 (en) 2005-06-09 2010-08-10 University Of Maryland Affinity membrane for capture of a target biomolecule and formation thereof by site-directed immobilization of a capture biomolecule
JP2007089548A (ja) * 2005-09-30 2007-04-12 Univ Of Tokushima シグナル増幅方法
CN101008644A (zh) * 2006-01-27 2007-08-01 陈云 功能性中枢神经损伤诊断检测用蛋白芯片及其制造方法
US8367351B2 (en) * 2006-05-05 2013-02-05 Historx, Inc. Methods for determining signal transduction activity in tumors
US20080108091A1 (en) * 2006-08-07 2008-05-08 Hennessy Bryan T Proteomic Patterns of Cancer Prognostic and Predictive Signatures
BRPI0717416A2 (pt) 2006-09-21 2013-11-12 Prometheus Lab Inc Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo
KR101485303B1 (ko) 2006-09-21 2015-01-22 네스텍 소시에테아노님 희귀 순환세포 내의 다수의 신호전달인자를 검출하기 위한 항체 기반 분석법
WO2008073581A2 (en) * 2006-10-23 2008-06-19 The Uab Research Foundation Biomarkers for cancer sensitivity to an anti-cancer agent and uses thereof
US20100234417A1 (en) 2006-11-10 2010-09-16 Dimerix Bioscience Pty Ltd. Thyrotropin releasing hormone receptor-orexin receptor hetero-dimers/-oligomers
EP2097754B2 (en) 2006-11-28 2018-01-24 Daiichi Sankyo Europe GmbH Activated her3 as a marker for predicting therapeutic efficacy
JP2010522554A (ja) 2007-03-27 2010-07-08 ロゼッタ ゲノミックス エルティーディー． 癌の分類のための遺伝子発現サイン
JP2008292424A (ja) 2007-05-28 2008-12-04 Nippon Medical School 腫瘍の検出方法
RU2519647C2 (ru) 2007-07-13 2014-06-20 Нестек С.А. Выбор лекарственных средств для терапии рака легких с помощью матриц на основе антител
EP2065475A1 (en) 2007-11-30 2009-06-03 Siemens Healthcare Diagnostics GmbH Method for therapy prediction in tumors having irregularities in the expression of at least one VEGF ligand and/or at least one ErbB-receptor
NZ587420A (en) 2008-02-25 2012-07-27 Prometheus Lab Inc Drug selection for breast cancer therapy using antibody-based arrays
EP2454598B1 (en) 2009-07-15 2017-03-22 DiaTech Holdings, Inc. Drug selection for gastric cancer therapy using antibody-based arrays
US20120270745A1 (en) 2009-07-15 2012-10-25 Prometheus Laboratories Inc. Drug selection for cancer therapy by profiling signal transduction proteins in ascites or pleural efflux samples
US20130315933A1 (en) 2010-10-06 2013-11-28 Christoph Renner Antibodies Directed Against HLA-B27 Homodimers and Methods and Uses Thereof in Diagnosis and Therapy
US9719995B2 (en) 2011-02-03 2017-08-01 Pierian Holdings, Inc. Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling
US20120231965A1 (en) 2011-02-03 2012-09-13 Prometheus Laboratories Inc. Drug selection for colorectal cancer therapy using antibody-based arrays
US20130216523A1 (en) 2011-03-31 2013-08-22 Laboratory Corporation Of America Holdings Methods for Facilitating Diagnosis, Prognosis and Treatment of Cancer by Detecting HER1 Expression
WO2013033623A1 (en) 2011-09-02 2013-03-07 Nestec S.A. Profiling of signal pathway proteins to determine therapeutic efficacy

Also Published As

Publication number Publication date
JP2013174616A (ja) 2013-09-05
CA2923248A1 (en) 2009-09-03
CN103399144A (zh) 2013-11-20
MX2010009140A (es) 2010-12-20
AU2009219437B2 (en) 2014-10-16
CA2716826C (en) 2017-05-09
US8609349B2 (en) 2013-12-17
EP2602623A2 (en) 2013-06-12
IL222872A (en) 2014-11-30
US20100167945A1 (en) 2010-07-01
EP2602623B1 (en) 2015-09-16
EP2250498B1 (en) 2012-10-31
NZ600339A (en) 2013-12-20
CN103399144B (zh) 2015-10-28
ES2545760T3 (es) 2015-09-15
EP2602623A3 (en) 2013-10-16
CN102016581A (zh) 2011-04-13
IL207637A (en) 2013-04-30
IL222872A0 (en) 2012-12-31
CN102016581B (zh) 2014-07-30
CA2716826A1 (en) 2009-09-03
US8163499B2 (en) 2012-04-24
US20130045880A1 (en) 2013-02-21
DK2250498T3 (da) 2013-02-04
IL207637A0 (en) 2010-12-30
DK2602623T3 (en) 2015-11-09
JP5414701B2 (ja) 2014-02-12
JP5852047B2 (ja) 2016-02-03
IL225241A (en) 2015-04-30
US10436786B2 (en) 2019-10-08
US9274116B2 (en) 2016-03-01
US20160123984A1 (en) 2016-05-05
ES2398618T3 (es) 2013-03-20
HK1182441A1 (zh) 2013-11-29
ES2553390T3 (es) 2015-12-09
EP2618146A3 (en) 2013-11-06
WO2009108637A1 (en) 2009-09-03
HK1185414A1 (en) 2014-02-14
EP2618146B1 (en) 2015-06-17
JP2011514522A (ja) 2011-05-06
EP2618146A2 (en) 2013-07-24
NZ587420A (en) 2012-07-27
EP2250498A1 (en) 2010-11-17
US20140349865A1 (en) 2014-11-27
AU2009219437A1 (en) 2009-09-03

Similar Documents

Publication Publication Date Title
NZ617520A (en) Drug selection for breast cancer therapy using antibody-based arrays
NZ616755A (en) Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy
NZ705645A (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
WO2019028285A3 (en) Use of immune cell-specific gene expression for prognosis of prostate cancer and prediction of responsiveness to radiation therapy
WO2011153254A3 (en) Prostate cancer associated circulating nucleic acid biomarkers
MX2018011725A (es) Metodo para emplear expresion genica para determinar pronostico de cancer de prostata.
EP2420835A3 (en) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
WO2010004591A3 (en) Genetic variants for breast cancer risk assessment
Zhang et al. Simultaneous enzyme-free detection of multiple long noncoding RNAs in cancer cells at single-molecule/particle level
NZ612483A (en) Drug selection for malignant cancer therapy using antibody-based arrays
WO2012154567A3 (en) Human invasion signature for prognosis of metastatic risk
NZ748624A (en) Methods of selecting an individual who will benefit from treatment with a telomerase inhibitor using a formalin fixed paraffin embedded (ffpe) biological sample of solid tumor cancer cells
MX2010008496A (es) Metodo para la determinacion de sensibilidad a agente anticancerigeno.
NZ589251A (en) Novel marker for detection of bladder cancer
MX2015001441A (es) Aptamero epcam para la deteccion de celulas madre cancerosas.
MX2013000502A (es) Metodos y kits para el diagnostico de cancer de prostata.
WO2011087709A3 (en) Eml4-alk translocations in lung cancer
WO2008031839A3 (en) Gene expression signature for the prognosis, diagnosis, and therapy of prostate cancer and uses thereof
WO2007012811A3 (en) Prostate stem cell markers
MX2009009841A (es) Metodos para determinar la respuesta de la leucemia mieloide aguda al tratamiento con farnesiltransferasa.
EP2619587A4 (en) BIOMARKERS FOR RECURRENCE PREDICTION OF COLORECTAL CANCER
WO2009052159A3 (en) Methods for selecting active agents for cancer treatment
WO2005087948A3 (en) Cancer treatment and assays for determining resistance to platinum-based chemotherapeutic agent
WO2011085276A3 (en) Methods and kits to predict prognostic and therapeutic outcome in small cell lung cancer
WO2009126804A3 (en) Expression of kir in human cancer cells as a biomarker for immuno-escape and cancer metastasis

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 4 YEARS UNTIL 24 FEB 2017 BY SHELSTON IP PTY LTD

Effective date: 20160504

LAPS Patent lapsed